Methods of treatment using igf-1 chimeric proteins

An IGF-1 chimeric protein for use in a method of treating a subject in need thereof, the method comprising:

• administering a solution comprising an effective amount of dextrose prior to administration of the IGF-1 chimeric protein, wherein the administering is over a period of about 48 hours;
• and administering a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein,
• wherein the effective amount of dextrose supports euglycemia.

Dextrose for use in a method of treating a subject in need thereof with an IGF-1 chimeric protein, the method comprising:

• administering a solution comprising an effective amount of said dextrose prior to administration of the IGF-1 chimeric protein, wherein the administering is over a period of about 48 hours;
• and administering a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein,
• wherein the effective amount of dextrose supports euglycemia.

A combination of an IGF-1 chimeric protein and dextrose for use in a method of treating a subject in need thereof, the method comprising:

• administering a solution comprising an effective amount of dextrose prior to administration of the IGF-1 chimeric protein, wherein the administering is over a period of about 48 hours;
• and administering a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein,
• wherein the effective amount of dextrose supports euglycemia.

Use of an IGF-1 chimeric protein in the manufacture of a medicament for treating a subject in need thereof, wherein a solution comprising an effective amount of dextrose is administered prior to administration of a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein IGF-1 chimeric protein, wherein administration of the solution is over a period of about 48, wherein the effective amount of dextrose supports euglycemia.

Use of dextrose with an IGF-1 chimeric protein in the manufacture of a medicament for treating a subject in need thereof, wherein a solution comprising an effective amount of the dextrose is administered prior to administration of a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein IGF-1 chimeric protein, wherein administration of the solution comprising the effective amount of the dextrose is over a period of about 48, wherein the effective amount of dextrose supports euglycemia.

Use of a combination of IGF-1 chimeric protein and dextrose in the manufacture of a medicament for treating a subject in need thereof, wherein a solution comprising an effective amount of the dextrose is administered prior to administration of a pharmaceutical composition comprising an effective amount of the IGF-1 chimeric protein IGF-1 chimeric protein, wherein administration of the solution comprising the effective amount of the dextrose is over a period of about 48, wherein the effective amount of dextrose supports euglycemia.